InMed Pharmaceuticals (INM) Accounts Payables (2020 - 2026)

InMed Pharmaceuticals' Accounts Payables history runs 7 years deep, the most recent figure standing at $1.0 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 28.24% year-over-year to $1.0 million in Q1 2026; TTM through Mar 2026 was $1.0 million, a 28.24% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, down 25.58% from the prior year.
• Accounts Payables retreated to $1.0 million in Q1 2026 per INM's latest filing, from $1.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $2.4 million in Q2 2022 and bottomed at $2000.0 in Q3 2024.
• The 5-year median for Accounts Payables is $1.3 million (2022), against an average of $1.3 million.
• Across the five-year window, Accounts Payables sank 99.47% in 2024 and surged 56410.95% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $2.0 million in 2022, then slumped by 34.65% to $1.3 million in 2023, then increased by 6.49% to $1.4 million in 2024, then declined by 21.83% to $1.1 million in 2025, then declined by 5.63% to $1.0 million in 2026.
• Per Business Quant, the three latest INM Accounts Payables figures stand at $1.0 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025).